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Summary
Recognition of the link between non-alcoholic fatty liver disease (NAFLD) and
cardiovascular disease (CVD) has boosted research in this area. The main objec-
tive of this paper is to review the literature on NAFLD in the context of CVD,
focussing on underlying mechanisms and treatment. Besides excessive fatty acid
influx, etiologic factors may include components of the metabolic syndrome,
cytokines and mitochondrial dysfunction. NAFLD is associated with both hepatic
and systemic insulin resistance. In the case of NAFLD, the liver overproduces
several atherogenic factors, notably inflammatory cytokines, glucose, lipoproteins
and coagulation factors, and factors increasing blood pressure. Intervention
studies on diet and laparoscopic surgery revealed improvements of hepatic fat
content and CVD risk profile. Pharmacological approaches with potential benefit
have been developed as well, but effects are often confounded by weight change.
NAFLD is associated with an increased CVD risk profile (and hepatic risk). In
order to improve CVD risk profile, prevention and treatment of NAFLD seem
advisable. However, well-designed intervention studies, randomized clinical trials
and long-term follow-up studies are scarce.
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Introduction
The global increase of overweight and obesity is alarming
(1), as obesity is a risk factor for many diseases including
cardiovascular disease (CVD) (2). Obesity has the highest
CVD risk when fat is located in the abdominal region (3).
In the case of obesity accompanied by insulin resistance,
triglycerides (TGs) are often excessively stored ectopically,
i.e. in organs and muscles rather than in adipocytes. When
TGs accumulate within hepatocytes (HCs; Fig. 1), a patho-
logical condition usually referred to as fatty liver disease
(FLD) will develop. FLD includes a wide spectrum, which
can broadly be divided into steatosis and steatohepatitis
(4). Non-alcoholic fatty liver disease (NAFLD) is used to
describe FLD in a person who drinks no or little alcohol
prior to diagnosis. In the literature, the amount of ethanol
allowed for the diagnosis of NAFLD varies greatly but is
maximally 20 g d-1 for women and 30 g d-1 for men. The
prevalence of NAFLD in the general adult western popu-
lation is relatively high, i.e. 20% (5,6); whereas, the preva-
lence of total FLD, including both NAFLD and alcoholic
FLD, is approximately 30% (5). In obese non-diabetic
western adults, the prevalence of NAFLD ranges from
80.4% to 97.9% (7,8).
Although there is a hepatic risk for patients with NAFLD,
notably cirrhosis (9) and hepatocarcinoma (10), the CVD
risk for patients with NAFLD may be higher (10). Few
studies have revealed evidence of an association between
NAFLD and early CVD markers (11), CVD events (12,13)
and CVD mortality (10). Follow-up of patients with
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NAFLD showed a higher incidence of CVD compared with
controls (10,13). A study by Hamaguchi et al. revealed that
NAFLD was an independent predictor, even stronger than
the metabolic syndrome, for first time CVD events (13).
The recognition of the CVD risk of NAFLD has boosted
research in this area during the recent years. We have
reviewed the literature on NAFLD in the context of CVD
risk profile markers. In this paper, after a short description
of the aetiology of NAFLD, we provide an overview of the
cardiovascular risk of NAFLD. Finally, the potential need
for prevention and treatment of NAFLD in order to
improve CVD risk profile is addressed.
Aetiology
The aetiology of the hepatic lipid imbalance underlying
the pathophysiology of NAFLD has been increasingly
unravelled. Besides excessive non-esterified fatty acid
influx, mediating factors may include: (i) components of
the metabolic syndrome (14,15); (ii) cytokines (16–24)
and (iii) mitochondrial dysfunction (25) (Fig. 1). A study
on the incidence of NAFLD suggested that the metabolic
syndrome precedes NAFLD (14), with insulin resistance
as a cornerstone (15). Animal models, reviewed by Diehl
et al. (16), revealed involvement of the cytokine tumour
necrosis factor-alpha (TNF-a) and its possible antagonist
adiponectin (17) in the pathogenesis of NAFLD. This is
reinforced by cross-sectional studies showing changes in
mRNA of both TNF-a receptors (increase) and adiponec-
tin receptors (decrease) in NAFLD (18–20). TNF-a,
recently reviewed by Ryden and Arner, may have numer-
ous mediating actions, among others increasing insulin
resistance and inhibiting fatty acid oxidation (22). Several
animal studies on adiponectin, recently reviewed by
Lafontan and Viguerie, suggest opposite actions of adi-
ponectin on energy metabolism, i.e. increasing insulin
sensitivity and stimulation of fatty acid oxidation (23).
Additionally, adiponectin might contribute to inhibition
Systemic cytokine influx, a.o. TNF-a≠ / adiponectinØ:






• From ≠ nutrition
• From ≠visceral fat
• From ≠ peripheral fat























a.o. Fibrinogen≠b, Factor VII≠, PAI-1≠
Anti-heamostatic factors:


























Figure 1 Model on the cardiovascular risk of non-alcoholic fatty liver disease. ↑, increase; ↓, decrease; a , dependent on pancreatic b-cell function;
b , may decrease in advanced NAFLD; Adipo-R1, adiponectin receptor 1; Adipo-R2, adiponectin receptor 2; AGEs, advanced glycation endproducts;
GLUT-4, glucose transporter 4; HDL-R, high-density lipoprotein receptor; I-R, insulin receptor; LDL-R, low-density lipoprotein receptor; NEFA-FF,
non-esterified fatty acid flip-flopping; NEFA-TP, non-esterified fatty acid transport protein; SAA, serum amyloid A; sTNF-R2; soluble tumour necrosis
factor-alpha receptor 2; TNF-R1; tumour necrosis factor-alpha receptor 1.
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of lipogenesis (24). Polymorphisms in the gene encoding
adiponectin receptor 1 are associated with the presence of
high hepatic fat content (and insulin resistance) (21).
Mitochondrial dysfunction (in non-alcoholic steatohepati-
tis [NASH]), recently reviewed by Begriche et al., can be
caused by oxidative stress, and may result in TG accu-
mulation and eventually cell death, i.e. necrosis (25).
Fatty liver-derived cardiovascular disease
risk factors
The liver secretes numerous CVD risk factors, notably
cytokines, glucose, lipoproteins, coagulation factors and
factors increasing blood pressure. In the case of NAFLD,
production of several of these risk factors is altered (Fig. 1).
Inflammation
In both patients with non-alcoholic steatosis (NAS) and
NASH, analysis of liver biopsies revealed hepatic distribu-
tion (mRNA) of the inflammatory cytokine TNF-a with its
receptors (18,20) and the anti-inflammatory adipocytokine
adiponectin with its receptors (20). As suggested by animal
models, the increased amount of fatty acids present in the
case of NAFLD may mediate hepatic production of TNF-a,
causing increased levels of systemic TNF-a (26). Upon HC
damage activated liver-specific macrophages ‘Kupffer Cells’
will secrete more cytokines into the blood, among others
TNF-a (18) and interleukin 6 (IL-6) (16,27,28). TNF-a
and IL-6 are considered to induce hepatic production of the
acute phase protein ‘C-reactive protein’ (CRP) (29).
Hepatic expression of TNF-a mRNA is significantly
higher in patients with NASH compared with NAS (18,20),
and hepatic expression of adiponectin mRNA is signifi-
cantly lower in patients with NASH compared with
NAS (20). Systemic TNF-a concentration is significantly
elevated in both patients with NAS and NASH (19). Both
hepatic IL-6 mRNA and systemic IL-6 concentration are
elevated in patients with NAS and the highest in NASH
(28). Elevated CRP is present in 25% of controls compared
with 60% of NAFLD patients (P = 0.003) (30). Fasting
adiponectin concentration predicts hepatic fat content
(31,32) and is significantly lower in both patients with
NASH and NAS compared with controls (19,32) for both
men and women (19). Fasting adiponectin is inversely cor-
related with hepatic fat content in healthy non-diabetic
subjects (31,33) but non-significantly in patients with type
2 diabetes mellitus (n = 10) (31). TNF-a, IL-6 and CRP
may contribute to the inflammatory CVD milieu, predis-
posing to atherosclerosis and CVD (34–36). On the con-
trary, studies in both humans and animals (23,37) have
revealed both anti-inflammatory (23) and antithrombotic
(37) properties of adiponectin, enabling a protective asso-
ciation between adiponectin and CVD (38).
In addition to a direct predisposition to atherosclerosis,
cytokines may have an indirect effect as well, as cytokines
may mediate insulin resistance (Fig. 1). Animal models
(22,39) and both in vitro (40) and in vivo (41) human
studies provided evidence that not fat accumulation itself
but fat-derived cytokines play a role in (obesity-related)
insulin resistance. The pleiotropic cytokine TNF-a inter-
feres with the hepatic insulin receptor and the intra-
hepatocellular insulin signalling cascade (22,40), causing
both hepatic and systemic insulin resistance (22,40).
Additionally, administration of human recombinant
TNF-a in human cancer patients resulted in increased
levels of very low-density lipoprotein (VLDL) and
TG and decreased levels of high-density lipoprotein
(HDL) (41), which are features of diabetic dyslipideamia
(42).
Hyperglycaemia and diabetic dyslipideamia
In the healthy situation, insulin stimulates hepatic and
peripheral glucose uptake and suppresses hepatic glucose
production. In patients with NAFLD, hepatic glucose
uptake may be less effectively stimulated by insulin,
contributing to elevated plasma glucose concentrations
(40,43). Moreover, hepatic glucose production might be
less effectively suppressed by insulin (40) but not in non-
diabetic NAFLD patients (43,44).
Hepatic fat content correlates positively with fasting
glucose (45), glucose levels after an oral glucose tolerance
test (46), fasting C-peptide (45), fasting insulin (45) and
insulin resistance by homeostatic model assessment (31). In
the general population, the odds ratio of NAFLD compared
with normal liver is 9.1 for hyperglycaemia (6). Addition-
ally, the odds ratios of NAFLD, compared with normal
liver, increase with increasing insulin quartile (4.2, 5.9 and
20.0 for the second, third and fourth quartile respectively)
and insulin resistance by homeostatic model assessment
quartile (2.3, 4.4 and 16.7 for the second, third and fourth
quartile respectively) (6). Plasma glucose and its advanced
glycation endproducts are considered atherogenic (47,48)
and predispose to CVD (49).
In the healthy situation, insulin suppresses hepatic pro-
duction and secretion of VLDL (50). In patients with
NAFLD, VLDL secretion is less effectively suppressed by
insulin, causing increased systemic VLDL-TG concentra-
tions (31). Hepatic fat content correlates positively with
VLDL1-TG and VLDL1-apolipoprotein-B secretion rates
(31). Besides the presence of NAFLD, the altered hepatic
lipid composition present in the case of NAFLD (51,52)
might play a role in both altered VLDL secretion rates and
altered lipoprotein composition. An in vitro study sug-
gested that the presence of different types of fatty acids in
the liver results in both different VLDL-apolipoprotein-B
secretion rates and lipoprotein composition (53).
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In patients with NAFLD, VLDL concentration is
increased, VLDL particles are larger, small dense LDL par-
ticles predominate, whereas large HDL particle concen-
tration is decreased (54). Hepatic fat content correlates
inversely with fasting HDL cholesterol concentration (45).
In the general population, the odds ratios of NAFLD com-
pared with normal liver are 6.3 for low-HDL cholesterol
concentration and 3.5 for hypertriglyceraemia (6). Systemic
lipids, i.e. TGs (48,55) and cholesterol (HDL excluded)
(47,55), have been considered atherogenic and predispose
to CVD (48,55).
Coagulation
Many coagulation factors are synthesized by HCs (56,57).
The limited data on the association between obesity-
independent markers of NAFLD, among others coagula-
tion factors, has recently been reviewed by Kotronen
and Yki-Jarvinen (45). In patients with NAFLD, the liver
overproduces several factors (Fig. 1), of which plasminogen
activator inhibitor-1 has direct atherogenic effects (47).
However, many factors (fibrinogen, protein C and protein
S) are increased in NAS but tend to be lower in NASH (58).
This may suggest that initially increased factors will
decrease while NAS progresses to advanced NASH. In
advanced liver disease, bleeding problems are well known
to occur (56,57).
Blood pressure
HCs produce angiotensinogen (59,60), a precursor of
angiotensin II. Upon HC damage activated Hepatic Stellate
Cells even synthesize and secrete mature angiotensin II
(61). Angiotensin II is a major pro-atherogenic and vaso-
constrictive peptide/neurotransmitter (47,61), considered
to predispose to elevated blood pressure (59–61) and pos-
sibly CVD (62). Both systolic (only in females) and diastolic
blood pressures correlate with hepatic fat content (45). In
the general population, univariate odds ratios of NAFLD,
compared with normal liver, are 2.0 for systolic hyperten-
sion and 1.7 for diastolic hypertension (6).
Prevention and treatment
As obesity (1), including childhood obesity (63), has been
increasing in the general population, an earlier peak preva-
lence of NAFLD and an increased CVD risk profile may be
expected in the future, delineating the need for prevention.
Once NAFLD is present, treatment seems advisable to
improve CVD risk profile and hepatic risk. Prevention
and treatment trials of NAFLD should focus on etiologic
factors, notably systemic non-esterified fatty acid influx,
components of the metabolic syndrome, cytokines and
mitochondrial dysfunction (Fig. 1). Several studies have
investigated the effect of lowering hepatic fat content on
improving CVD risk profile markers; however, no longi-
tudinal studies on lowering CVD events have been per-
formed yet.
For an overview on diagnosis modalities for NAFLD, the
reader is referred to recent review papers (45,64). As serum
levels of transferases are of limited use (45,64,65), the
intervention studies included in Table 1 have been limited
to studies with a diagnosis by histology or imaging.
Dietary (plus exercise) and laparoscopic surgery inter-
ventions (3–15 months) revealed that overall loss of
adipose tissue, determined by a decreased body mass index
(BMI) (2.6–18.2 BMI points), promotes loss of hepatic fat
content and results in an improved CVD risk profile (66–
70). This suggests that weight loss should be pursued in
patients with NAFLD.
Patients unable to lose weight or non-overweight
patients might benefit from drug treatment. However, no
medication is currently licensed for NAFLD treatment even
though some have shown potential benefit. Additionally, as
weight loss is associated with an improvement of NAFLD
(66–70), statistical adjustment for the amount of weight
change as potential confounder (Table 1) should be con-
sidered when determining true effects of pharmacological
interventions. For an overview on potential treatment
modalities, the reader is referred to recent review papers
(45,64).
Some of the most often prescribed medicine are based on
improving CVD risk profile (components of the metabolic
syndrome) by acting on hepatic lipid metabolism, e.g.
statins and fibrates (71,72) and by acting on hepatic
glucose metabolism, e.g. metformin (73). Although often
prescribed, studies on statins (74), fibrates (75) and met-
formin (76,77) in the case of NAFLD are few, often accom-
panied by weight loss and inconclusive. Studies on the
angiotensin II receptor antagonist losartan revealed benefi-
cial histological results (74,78).
As the possible antagonists TNF-a and adiponectin (17)
may be involved in both the aetiology of NAFLD (16–24)
and the worsening of CVD risk profile (23,34–38), TNF-
a-lowering in NAFLD might be beneficial to improve both
NAFLD and CVD risk profile, as suggested by studies on
pentoxifylline (74,79).
Conclusion
TheNAFLD is associatedwith an increasedCVD risk profile
(and hepatic risk). In order to improve CVD risk profile,
prevention and treatment of NAFLD seem advisable.
However, well-designed intervention studies, randomized
clinical trials and long-term follow-up studies are scarce.
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